BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 18260034)

  • 1. Molecular characterization of musculoskeletal tumors by proton MR spectroscopy.
    Fayad LM; Barker PB; Bluemke DA
    Semin Musculoskelet Radiol; 2007 Sep; 11(3):240-5. PubMed ID: 18260034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preliminary study of 3T 1H MR spectroscopy in bone and soft tissue tumors.
    Qi ZH; Li CF; Li ZF; Zhang K; Wang Q; Yu DX
    Chin Med J (Engl); 2009 Jan; 122(1):39-43. PubMed ID: 19187615
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Longitudinally monitoring chemotherapy effect of malignant musculoskeletal tumors with in vivo proton magnetic resonance spectroscopy: an initial experience.
    Hsieh TJ; Li CW; Chuang HY; Liu GC; Wang CK
    J Comput Assist Tomogr; 2008; 32(6):987-94. PubMed ID: 19204465
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proton magnetic resonance spectroscopy of musculoskeletal lesions at 3 T with metabolite quantification.
    Lee CW; Lee JH; Kim DH; Min HS; Park BK; Cho HS; Kang HG; Suh JS; Ehara S
    Clin Imaging; 2010; 34(1):47-52. PubMed ID: 20122519
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of musculoskeletal lesions on 3-T proton MR spectroscopy.
    Fayad LM; Barker PB; Jacobs MA; Eng J; Weber KL; Kulesza P; Bluemke DA
    AJR Am J Roentgenol; 2007 Jun; 188(6):1513-20. PubMed ID: 17515370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MR spectroscopy of musculoskeletal soft-tissue tumors.
    Negendank WG
    Magn Reson Imaging Clin N Am; 1995 Nov; 3(4):713-25. PubMed ID: 8564691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of MRS in the differentiation of benign and malignant soft tissue and bone tumors.
    Doganay S; Altinok T; Alkan A; Kahraman B; Karakas HM
    Eur J Radiol; 2011 Aug; 79(2):e33-7. PubMed ID: 21376496
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo 1H MRS for musculoskeletal lesion characterization: which factors affect diagnostic accuracy?
    Wang CK; Li CW; Hsieh TJ; Lin CJ; Chien SH; Tsai KB; Chang KC; Tsai HM
    NMR Biomed; 2012 Feb; 25(2):359-68. PubMed ID: 21793078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of bone and soft-tissue tumors with in vivo 1H MR spectroscopy: initial results.
    Wang CK; Li CW; Hsieh TJ; Chien SH; Liu GC; Tsai KB
    Radiology; 2004 Aug; 232(2):599-605. PubMed ID: 15286325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ex vivo proton MR spectroscopy (1H-MRS) for evaluation of human gastric carcinoma.
    Mun CW; Cho JY; Shin WJ; Choi KS; Eun CK; Cha SS; Lee J; Yang YI; Nam SH; Kim J; Lee SY
    Magn Reson Imaging; 2004 Jul; 22(6):861-70. PubMed ID: 15234456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Magnetic resonance imaging of primary musculoskeletal tumors.
    Pettersson H; Hamlin DJ; Scott KN
    Crit Rev Diagn Imaging; 1986; 26(3):241-63. PubMed ID: 3536307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo proton spectroscopy of giant cell tumor of the bone.
    Sah PL; Sharma R; Kandpal H; Seith A; Rastogi S; Bandhu S; Jagannathan NR
    AJR Am J Roentgenol; 2008 Feb; 190(2):W133-9. PubMed ID: 18212197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proton MR spectroscopy of the prostate.
    Mueller-Lisse UG; Scherr MK
    Eur J Radiol; 2007 Sep; 63(3):351-60. PubMed ID: 17709223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Application value of 3T 1H-magnetic resonance spectroscopy in diagnosing tumors of bone and soft tissue].
    Qi ZH; Li CF; Ma XX; Li ZF; Zhang K; Yu DX
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2011 Oct; 33(5):504-10. PubMed ID: 22338133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic changes in pelvic lesions: findings at proton MR spectroscopic imaging.
    Hascalik S; Celik O; Sarac K; Meydanli MM; Alkan A; Mizrak B
    Gynecol Obstet Invest; 2005; 60(3):121-7. PubMed ID: 15920339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Malignancy assessment of brain tumours with magnetic resonance spectroscopy and dynamic susceptibility contrast MRI.
    Fayed N; Dávila J; Medrano J; Olmos S
    Eur J Radiol; 2008 Sep; 67(3):427-33. PubMed ID: 18442889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Study of single voxel 1H MR spectroscopy of bone tumors: differentiation of benign from malignant tumors.
    Zhang J; Cheng K; Ding Y; Liang W; Ding Y; Vanel D; Cheng X
    Eur J Radiol; 2013 Dec; 82(12):2124-8. PubMed ID: 22169357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative multivoxel proton chemical shift imaging of the breast.
    Sijens PE; Dorrius MD; Kappert P; Baron P; Pijnappel RM; Oudkerk M
    Magn Reson Imaging; 2010 Apr; 28(3):314-9. PubMed ID: 20071119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of gadolinium in the MR evaluation of musculoskeletal tumors.
    Kransdorf MJ
    Top Magn Reson Imaging; 1996 Feb; 8(1):15-23. PubMed ID: 8820091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary tumors of the musculoskeletal system.
    Vanel D; Verstraete KL; Shapeero LG
    Radiol Clin North Am; 1997 Jan; 35(1):213-37. PubMed ID: 8998216
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.